FavipiravirDisseminated erythematous drug eruption following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1982卷 / 1期

关键词：

D O I：

10.1007/s40278-023-49125-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：188 / 188

相关论文

共 50 条

[41] DapsoneMethaemoglobinaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1843 (1) : 130 - 130
[42] NalbuphineBradycardia following an off-label use: case report
[J]. Reactions Weekly, 2019, 1753 (1) : 255 - 255
[43] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2020, 1802 (1) : 114 - 114
[44] CyproteroneMeningiomas following off-label use: case report
[J]. Reactions Weekly, 2021, 1849 (1) : 152 - 152
[45] HydroxychloroquineHaemolysis following off-label use: case report
[J]. Reactions Weekly, 2021, 1836 (1) : 376 - 376
[46] GlibenclamideHypoglycaemia following an off-label use : case report
[J]. Reactions Weekly, 2021, 1866 (1) : 190 - 190
[47] SintilimabFasciitis following off-label use: case report
[J]. Reactions Weekly, 2021, 1884 (1) : 391 - 391
[48] HydroxychloroquineEosinophilia following off-label use: case report
[J]. Reactions Weekly, 2021, 1867 (1) : 204 - 204
[49] DexamethasoneMucormycosis following off-label use: case report
[J]. Reactions Weekly, 2023, 1956 (1) : 181 - 181
[50] PralatrexateStomatitis following off-label use: case report
[J]. Reactions Weekly, 2021, 1842 (1) : 309 - 309

← 1 2 3 4 5 →